Figure 1.

First occurrence of docetaxel dose reduction <75 mg/m² by study treatment cycle in the safety population according to treatment received and geographic region: Asia versus other regions (Europe, North America, and South America). Overall, docetaxel dose reductions below 75 mg/m² were most commonly performed at cycle 2 (data in bold). Data are presented up until cycle 9, the median number of docetaxel cycles in patients from Asia. ∗, n, number of patients with first occurrence of docetaxel dose reduction <75 mg/m²; N, number of patients receiving any docetaxel dose at a given cycle. ‡, Sum of patients with first occurrence of docetaxel dose reduction <75 mg/m² in cycles 1−5, cycles 6−9, and cycle 10 until the end of docetaxel treatment.

Abbreviations: D, docetaxel; Pla, placebo; pts, patients; Ptz, pertuzumab; T, trastuzumab; treat., treatment.